Daré Bioscience, Inc., a biopharmaceutical company, has announced positive interim results from its ongoing Phase 3 clinical trial of Ovaprene®, an investigational hormone-free, monthly intravaginal contraceptive. The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene. Interim findings revealed that approximately 9% of participants experienced pregnancy, aligning with the company's expectations from previous studies. No serious safety concerns were identified, with favorable overall tolerability reported. The study's Data Safety Monitoring Board recommended continuing the trial without modifications. Final results and analysis of study endpoints, including the pregnancy rate calculated using the Pearl Index, are anticipated upon the study's completion. Currently, there are no FDA-approved hormone-free, monthly intravaginal contraceptives on the market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。